기면병, 어떻게 치료할 것인가?

키워드

참고문헌 (59)

1. American Academy of Sleep Medicine, "International classification of sleep disorders" (2014), American Academy of Sleep Medicine
2. Kornum BR, "Narcolepsy", Nat Rev Dis Primers, 3, pp.16100~ (2017)
3. Ohayon MM, "Narcolepsy and hypersomnia", pp.125~132 (2007), Taylor and Francis
4. 한진규, "기면증의 약물 치료", Journal of sleep medicine, 1(2), pp.15~19 (2004), 대한수면연구학회
5. Thorpy MJ, "Update on the pharmacologic management of narcolepsy : mechanisms of action and clinical implications", Sleep Med, 68, pp.97~109 (2020)
6. Cho JW, "Sleep disorders: case-based learning", pp.197~226 (2020), PanMun Education
7. Minzenberg MJ, "Modafinil : a review of neurochemical actions and effects on cognition", Neuropsychopharmacology, 33, pp.1477~1502 (2008)
8. Volkow ND, "Effects of modafinil on dopamine and dopamine transporters in the male human brain : clinical implications", JAMA, 301, pp.1148~1154 (2009)
9. Wisor JP, "Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil", Neuroscience, 132, pp.1027~1034 (2005)
10. Broughton RJ, "Randomized, doubleblind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy", Neurology, 49, pp.444~451 (1997)
11. Moldofsky H, "A randomized trial of the longterm, continued efficacy and safety of modafinil in narcolepsy", Sleep Med, 1, pp.109~116 (2000)
12. Schwartz JR, "Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea : a 12-week, open-label study", Chest, 124, pp.2192~2199 (2003)
13. Loland CJ, "R-modafinil(armodafinil) : a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse", Biol Psychiatry, 72, pp.405~413 (2012)
14. Harsh JR, "The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy", Curr Med Res Opin, 22, pp.761~774 (2006)
15. Darwish M, "Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives : analysis of data from three randomized, single-dose, pharmacokinetic studies", Clin Drug Investig, 29, pp.613~623 (2009)
16. Dauvilliers Y, "Narcolepsy and other central hypersomnias", Continuum(Minneap Minn), 23, pp.989~1004 (2017)
17. Kallweit U, "Pharmacological management of narcolepsy with and without cataplexy", Expert Opin Pharmacother, 18, pp.809~817 (2017)
18. Pauly V, "Patterns and profiles of methylphenidate use both in children and adults", Br J Clin Pharmacol, 84, pp.1215~1227 (2018)
19. Syed YY, "Pitolisant : first global approval", Drugs, 76, pp.1313~1318 (2016)
20. "Wakix (pitolisant)" (2019)[URL]
21. Dauvilliers Y, "Pitolisant versus placebo or modafinil in patients with narcolepsy : a double-blind, randomised trial", Lancet Neurol, 12, pp.1068~1075 (2013)
22. Szakacs Z, "Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy : a randomised, double-blind, placebo-controlled trial", Lancet Neurol, 16, pp.200~207 (2017)
23. Li S, "Pitolisant for treating patients with narcolepsy", Expert Rev Clin Pharmacol, 13, pp.79~84 (2020)
24. Barateau L, "Recent advances in treatment for narcolepsy", Ther Adv Neurol Disord, 12, pp.1756286419875622~ (2019)
25. "SunosiTM (solriamfetol) tablets, for oral use, CIV", Jazz Pharmaceuticals, Inc., ~ (2019)
26. Baladi MG, "Characterization of the neurochemical and behavioral effects of solriamfetol(JZP-110), a selective dopamine and norepinephrine reuptake inhibitor", J Pharmacol Exp Ther, 366, pp.367~376 (2018)
27. Thorpy MJ, "A randomized study of solriamfetol for excessive sleepiness in narcolepsy", Ann Neurol, 85, pp.359~370 (2019)
28. Emsellem HA, "Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy", Sleep Med, 67, pp.128~136 (2020)
29. Malhotra A, "Long-term study of the safety and maintenance of efficacy of solriamfetol(JZP-110)in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea", Sleep, 43, pp.zsz220~ (2020)
30. Alshaikh MK, "Sodium oxybate for narcolepsy with cataplexy : systematic review and meta-analysis", J Clin Sleep Med, 8, pp.451~458 (2012)
31. Black J, "Sodium oxybate improves excessive daytime sleepiness in narcolepsy", Sleep, 29, pp.939~946 (2006)
32. Bogan RK, "Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy", J Clin Sleep Med, 11, pp.427~432 (2015)
33. Wang J, "Status cataplecticus precipitated by abrupt withdrawal of venlafaxine", J Clin Sleep Med, 9, pp.715~716 (2013)
34. Thorpy MJ, "Update on therapy for narcolepsy", Curr Treat Options Neurol, 17, pp.347~ (2015)
35. Dauvilliers Y, "Cataplexy--clinical aspects, pathophysiology and management strategy", Nat Rev Neurol, 10, pp.386~395 (2014)
36. Swick TJ, "Treatment paradigms for cataplexy in narcolepsy : past, present, and future", Nat Sci Sleep, 7, pp.159~169 (2015)
37. Xyrem International Study Group, "Further evidence supporting the use of sodium oxybate for the treatment of cataplexy : a double-blind, placebo-controlled study in 228 patients", Sleep Med, 6, pp.415~421 (2005)
38. Lemon MD, "Sodium oxybate for cataplexy", Ann Pharmacother, 40, pp.433~440 (2006)
39. Gowda CR, "Mechanism of action of narcolepsy medications", CNS Spectr 2014;19 Suppl, 19(ppl), pp.25~34 (2014)
40. Morgenthaler TI, "Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin", Sleep, 30, pp.1705~1711 (2007)
41. Mignot E, "Emerging therapies in narcolepsy-cataplexy", Sleep, 28, pp.754~763 (2005)
42. Black SW, "Challenges in the development of therapeutics for narcolepsy", Prog Neurobiol, 152, pp.89~113 (2017)
43. Cochen De Cock V, "Current and future therapeutic approaches in narcolepsy", Future Neurol, 6, pp.771~782 (2011)
44. Mahlios J, "The autoimmune basis of narcolepsy", Curr Opin Neurobiol, 23, pp.767~773 (2013)
45. Dauvilliers Y, "Follow-up of four narcolepsy patients treated with intravenous immunoglobulins", Ann Neurol, 60, pp.153~ (2006)
46. Kallweit U, "Coexisting narcolepsy(with and without cataplexy)and multiple sclerosis : six new cases and a literature review", J Neurol, 265, pp.2071~2078 (2018)
47. Billiard M, "EFNS guidelines on management of narcolepsy", Eur J Neurol, 13, pp.1035~1048 (2006)
48. Donjacour CEHM, "Narcolepsy, driving and traffic safety", pp.217~221 (2010), Springer
49. Naumann A, "Narcolepsy : pathophysiology and neuropsychological changes", Behav Neurol, 14, pp.89~98 (2003)
50. Zamarian L, "Subjective deficits of attention, cognition and depression in patients with narcolepsy", Sleep Med, 16, pp.45~51 (2015)
51. Agudelo HAM, "MN-123 multicomponent cognitive behavioral treatment efficacy for narcolepsy(MCBT-N)", Sleep Med, 12, pp.S55~ (2011)
52. Conroy DA, "Behavioral management of hypersomnia", Sleep Med Clin, 7, pp.325~331 (2012)
53. Franceschini C, "Narcolepsy treatment : pharmacological and behavioral strategies in adults and children", Sleep Breath (2019)[DOI]
54. Thorpy MJ, "Delayed diagnosis of narcolepsy : characterization and impact", Sleep Med, 15, pp.502~507 (2014)
55. Filardi M, "Physical activity and sleep", wake behavior, anthropometric, and metabolic profile in pediatric narcolepsy Type 1, 2018, pp.9, 707~
56. Rogers AE, "A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy", Sleep, 24, pp.385~391 (2001)
57. Marín Agudelo HA, "Cognitive behavioral treatment for narcolepsy : can it complement pharmacotherapy", Sleep Sci, 7, pp.30~42 (2014)
58. Van Schie MK, "Sustained attention to response task(SART)shows impaired vigilance in a spectrum of disorders of excessive daytime sleepiness", J Sleep Res, 21, pp.390~395 (2012)
59. "Healthcare Bigdata Hub" (2020)[URL]

관련 논문AI추천